Alzheimer's disease is a progressive brain disorder characterized by memory loss, cognitive decline, and the accumulation of two hallmark proteins: amyloid and tau. Our lab pursues three interconnected lines of research into how amyloid accumulates, moves, and can be intercepted.
The first focuses on cerebral amyloid angiopathy (CAA), a vascular form of the pathology in which amyloid accumulates around blood vessels rather than in the surrounding brain tissue, impairing their function. Using intravital imaging, we traced this process to intercellular signaling that drives overexpression of an enzyme called soluble epoxide hydrolase. Blocking this enzyme reduced vascular amyloid and improved vessel function (deMeglio et al., Brain, 2026), identifying a potential new therapeutic target for a form of Alzheimer's disease that has proven difficult to treat.
The second examines how amyloid that accumulates in the brain parenchyma is cleared, specifically how it is transported across the blood-brain barrier and out of the brain into the bloodstream. We study the cellular and molecular steps of this clearance route and ask how the process might be enhanced, since a more efficient efflux pathway could reduce the amyloid burden before it drives further vascular and neuronal damage.
The third addresses the earliest phase of disease, before clinical symptoms appear. We track how amyloid begins to accumulate during this pre-symptomatic period and how it relates to the earliest signs of cellular dysfunction, with the aim of identifying this stage as a window for intervention. Because Alzheimer's pathology can precede symptoms by years, understanding what goes wrong at this early point is central to developing treatments that act before significant damage has occurred.